BR112022019713A2 - Composições que compreendem um polipeptídeo variante cas12i2 e usos das mesmas - Google Patents

Composições que compreendem um polipeptídeo variante cas12i2 e usos das mesmas

Info

Publication number
BR112022019713A2
BR112022019713A2 BR112022019713A BR112022019713A BR112022019713A2 BR 112022019713 A2 BR112022019713 A2 BR 112022019713A2 BR 112022019713 A BR112022019713 A BR 112022019713A BR 112022019713 A BR112022019713 A BR 112022019713A BR 112022019713 A2 BR112022019713 A2 BR 112022019713A2
Authority
BR
Brazil
Prior art keywords
cas12i2
variant
polypeptides
compositions
complexes
Prior art date
Application number
BR112022019713A
Other languages
English (en)
Inventor
Chong Shaorong
Jay Hilbert Brendan
Norman Wessells Quinton
Michael Jakimo Noah
Ziblat Roy
Michael Carte Jason
Marie Ditommaso Tia
Raymond Haswell Jeffrey
James Garrity Anthony
Alexander Mcgaw Colin
A Scott David
Michael Cerchione Derek
Original Assignee
Arbor Biotechnologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arbor Biotechnologies Inc filed Critical Arbor Biotechnologies Inc
Publication of BR112022019713A2 publication Critical patent/BR112022019713A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

COMPOSIÇÕES QUE COMPREENDEM UM POLIPEPTÍDEO VARIANTE CAS12I2 E USOS DAS MESMAS. A presente invenção refere-se a polipeptídeos Cas12i2 variantes, métodos para produzir os polipeptídeos Cas12i2 variantes, processos para caracterizar os polipeptídeos Cas12i2 variantes, células que compreendem os polipeptídeos Cas12i2 variantes e métodos para usar os polipeptídeos Cas12i2 variantes. A invenção refere-se, ainda, a complexos que compreendem os polipeptídeos Cas12i2 variantes, métodos para produzir os complexos, processos para caracterizar os complexos, células que compreendem os complexos e métodos para usar os complexos.
BR112022019713A 2020-03-31 2021-03-31 Composições que compreendem um polipeptídeo variante cas12i2 e usos das mesmas BR112022019713A2 (pt)

Applications Claiming Priority (19)

Application Number Priority Date Filing Date Title
US202063003090P 2020-03-31 2020-03-31
US202063002999P 2020-03-31 2020-03-31
US202063003064P 2020-03-31 2020-03-31
US202063012007P 2020-04-17 2020-04-17
US202063026562P 2020-05-18 2020-05-18
US202063026606P 2020-05-18 2020-05-18
US202063026523P 2020-05-18 2020-05-18
US202063026277P 2020-05-18 2020-05-18
US202063063831P 2020-08-10 2020-08-10
US202063063819P 2020-08-10 2020-08-10
US202063063859P 2020-08-10 2020-08-10
US202063063879P 2020-08-10 2020-08-10
US202063085792P 2020-09-30 2020-09-30
US202063085752P 2020-09-30 2020-09-30
US202063085862P 2020-09-30 2020-09-30
US202063085895P 2020-09-30 2020-09-30
US202163147850P 2021-02-10 2021-02-10
US202163147968P 2021-02-10 2021-02-10
PCT/US2021/025257 WO2021202800A1 (en) 2020-03-31 2021-03-31 Compositions comprising a cas12i2 variant polypeptide and uses thereof

Publications (1)

Publication Number Publication Date
BR112022019713A2 true BR112022019713A2 (pt) 2022-12-20

Family

ID=75640000

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022019713A BR112022019713A2 (pt) 2020-03-31 2021-03-31 Composições que compreendem um polipeptídeo variante cas12i2 e usos das mesmas

Country Status (12)

Country Link
US (1) US20230332119A1 (pt)
EP (1) EP4127154A1 (pt)
JP (1) JP2023520504A (pt)
KR (1) KR20230009379A (pt)
CN (1) CN115698278A (pt)
AU (1) AU2021249119A1 (pt)
BR (1) BR112022019713A2 (pt)
CA (1) CA3177749A1 (pt)
CO (1) CO2022015170A2 (pt)
IL (1) IL296791A (pt)
MX (1) MX2022012189A (pt)
WO (1) WO2021202800A1 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021243267A2 (en) * 2020-05-29 2021-12-02 Arbor Biotechnologies, Inc. Compositions comprising a cas12i2 polypeptide and uses thereof
WO2022094329A1 (en) * 2020-10-30 2022-05-05 Arbor Biotechnologies, Inc. Compositions comprising an rna guide targeting pdcd1 and uses thereof
US20240102007A1 (en) 2021-06-01 2024-03-28 Arbor Biotechnologies, Inc. Gene editing systems comprising a crispr nuclease and uses thereof
EP4347831A2 (en) 2021-06-04 2024-04-10 Arbor Biotechnologies, Inc. Gene editing systems comprising an rna guide targeting transthyretin (ttr) and uses thereof
EP4347833A2 (en) 2021-06-04 2024-04-10 Arbor Biotechnologies, Inc. Gene editing systems comprising an rna guide targeting hydroxyacid oxidase 1 (hao1) and uses thereof
WO2022256655A2 (en) 2021-06-04 2022-12-08 Arbor Biotechnologies, Inc. Gene editing systems comprising an rna guide targeting lactate dehydrogenase a (ldha) and uses thereof
WO2023018856A1 (en) 2021-08-11 2023-02-16 Arbor Biotechnologies, Inc. Gene editing systems comprising an rna guide targeting polypyrimidine tract binding protein 1 (ptbp1) and uses thereof
KR20240052763A (ko) 2021-08-11 2024-04-23 아버 바이오테크놀로지스, 인크. 스타스민 2 (stmn2)를 표적화하는 rna 가이드를 포함하는 유전자 편집 시스템 및 이의 용도
WO2023034475A1 (en) 2021-09-01 2023-03-09 Arbor Biotechnologies, Inc. Cells modified by a cas12i polypeptide
WO2023081377A2 (en) * 2021-11-05 2023-05-11 Arbor Biotechnologies, Inc. Compositions comprising an rna guide targeting ciita and uses thereof
WO2023122433A1 (en) 2021-12-22 2023-06-29 Arbor Biotechnologies, Inc. Gene editing systems targeting hydroxyacid oxidase 1 (hao1) and lactate dehydrogenase a (ldha)
WO2023138685A1 (en) * 2022-01-24 2023-07-27 Huidagene Therapeutics Co., Ltd. Novel crispr-cas12i systems and uses thereof
WO2023208003A1 (en) * 2022-04-25 2023-11-02 Huidagene Therapeutics Co., Ltd. Novel crispr-cas12i systems and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201707569YA (en) 2012-12-12 2017-10-30 Broad Inst Inc Delivery, Engineering and Optimization of Systems, Methods and Compositions for Sequence Manipulation and Therapeutic Applications
DK3066201T3 (en) 2013-11-07 2018-06-06 Editas Medicine Inc CRISPR-RELATED PROCEDURES AND COMPOSITIONS WITH LEADING GRADES
DK3765615T3 (da) * 2018-03-14 2023-08-21 Arbor Biotechnologies Inc Nye enzymer og systemer til målretning af crispr dna

Also Published As

Publication number Publication date
MX2022012189A (es) 2023-01-05
US20230332119A1 (en) 2023-10-19
EP4127154A1 (en) 2023-02-08
WO2021202800A1 (en) 2021-10-07
CO2022015170A2 (es) 2022-11-08
AU2021249119A1 (en) 2022-10-20
JP2023520504A (ja) 2023-05-17
CN115698278A (zh) 2023-02-03
IL296791A (en) 2022-11-01
KR20230009379A (ko) 2023-01-17
CA3177749A1 (en) 2021-10-07

Similar Documents

Publication Publication Date Title
BR112022019713A2 (pt) Composições que compreendem um polipeptídeo variante cas12i2 e usos das mesmas
AR120543A2 (es) Moléculas biespecíficas de células t activadas por proteasas
CO2022002630A2 (es) Compuestos inhibidores de rip1 y métodos para hacer y utilizar los mismos
CL2018003148A1 (es) Proteínas de fusión y usos de las mismas.
CL2019000259A1 (es) Anticuerpos, antimiostatina, polipéptidos que contienen regiones fc variantes y métodos de uso.(divisional solicitud 201701584)
CL2021003132A1 (es) Anticuerpos que se unen a cd3 (divisional de solicitud n° 202101506)
BR112018007017A2 (pt) polipeptídeos
BR112018012134A2 (pt) prótese de válvula cardíaca
BR112018011073A2 (pt) anticorpos antimiostatina, polipeptídeos contendo regiões fc variantes e métodos de utilização
CL2019001293A1 (es) Agentes, usos y métodos para el tratamiento de la sinucleinopatía.
BR112017008157A2 (pt) polipeptídeos de fgf-21 modificados e usos dos mesmos
UY36578A (es) Proteínas de unión a tslp
CO2023013171A2 (es) Composiciones que comprenden un polipéptido variante y usos de las mismas
BR112019012796A2 (pt) proteínas de ligação ao antígeno antineuropilina e métodos de uso das mesmas
BR112015021960A2 (pt) Células hospedeiras e métodos de uso
CO2022002374A2 (es) Compuestos inhibidores de rip1 y métodos para prepararlos y usarlos
BR112016000565A2 (pt) polipeptídeo cíclico, derivado ou análogo do mesmo e seu uso modulador alostérico, composição farmacêutica, processo para produzir a mesma
AR102445A1 (es) COMPOSICIONES Y MÉTODOS RELACIONADOS CON b-GLUCOSIDASA
BR112016015218A2 (pt) microrganismo com capacidade melhorada de produção de l-treonina e método para produzir l-treonina com o uso desse
BR112021025448A2 (pt) Variante de proteína de exportação de l-treonina e método para produção de l-treonina com o uso da mesma
BR112022008092A2 (pt) Métodos de preparação de uma amostra enriquecida para sequenciamento polipeptídico
BR112017001966A2 (pt) ?método para produzir variantes com um fc com sialilação melhorada?
BR112022017390A2 (pt) Microcápsulas do tipo núcleo-casca de coacervado
BR112017000637A2 (pt) pá de rotor de turbina eólica, método para produzir uma ponta de pá de rotor de turbina eólica, e, ponta de pá de rotor de turbina eólica.
CL2021002838A1 (es) Anticuerpo anti-bcma conjugado, composiciones que comprenden el mismo, y métodos de fabricación y uso del mismo.